Literature DB >> 26412154

The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease.

Wilfrid Mazier1, Nicolas Saucisse1, Blandine Gatta-Cherifi2, Daniela Cota3.   

Abstract

The endocannabinoid system (ECS) functions to adjust behavior and metabolism according to environmental changes in food availability. Its actions range from the regulation of sensory responses to the development of preference for the consumption of calorically-rich food and control of its metabolic handling. ECS activity is beneficial when access to food is scarce or unpredictable. However, when food is plentiful, the ECS favors obesity and metabolic disease. We review recent advances in understanding the roles of the ECS in energy balance, and discuss newly identified mechanisms of action that, after the withdrawal of first generation cannabinoid type 1 (CB1) receptor antagonists for the treatment of obesity, have made the ECS once again an attractive target for therapy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CB(1); Endocannabinoids; energy balance; food intake; metabolism; obesity

Mesh:

Substances:

Year:  2015        PMID: 26412154     DOI: 10.1016/j.tem.2015.07.007

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  60 in total

1.  Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes.

Authors:  Tony Jourdan; Gergő Szanda; Resat Cinar; Grzegorz Godlewski; David J Holovac; Joshua K Park; Sarah Nicoloro; Yuefei Shen; Jie Liu; Avi Z Rosenberg; Ziyi Liu; Michael P Czech; George Kunos
Journal:  Diabetes       Date:  2017-01-12       Impact factor: 9.461

2.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

3.  Peripheral Endocannabinoids Associated With Energy Expenditure in Native Americans of Southwestern Heritage.

Authors:  Sascha Heinitz; Alessio Basolo; Paolo Piaggi; Daniele Piomelli; Reiner Jumpertz von Schwartzenberg; Jonathan Krakoff
Journal:  J Clin Endocrinol Metab       Date:  2018-03-01       Impact factor: 5.958

Review 4.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

5.  Dietary Polysaccharides in the Amelioration of Gut Microbiome Dysbiosis and Metabolic Diseases.

Authors:  Shokouh Ahmadi; Rabina Mainali; Ravinder Nagpal; Mahmoud Sheikh-Zeinoddin; Sabihe Soleimanian-Zad; Shaohua Wang; Gagan Deep; Santosh Kumar Mishra; Hariom Yadav
Journal:  Obes Control Ther       Date:  2017-12-18

6.  Endocannabinoid Anandamide Mediates the Effect of Skeletal Muscle Sphingomyelins on Human Energy Expenditure.

Authors:  Sascha Heinitz; Alessio Basolo; Daniele Piomelli; Jonathan Krakoff; Paolo Piaggi
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

Review 7.  Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?

Authors:  Jürg Gertsch
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

8.  Structure-Activity Relationship Studies of Pyrimidine-4-Carboxamides as Inhibitors of N-Acylphosphatidylethanolamine Phospholipase D.

Authors:  Elliot D Mock; Ioli Kotsogianni; Wouter P F Driever; Carmen S Fonseca; Jelle M Vooijs; Hans den Dulk; Constant A A van Boeckel; Mario van der Stelt
Journal:  J Med Chem       Date:  2020-12-31       Impact factor: 7.446

9.  Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.

Authors:  Carmelo Quarta; Daniela Cota
Journal:  Int J Obes (Lond)       Date:  2020-04-21       Impact factor: 5.095

10.  Probing the CB1 Cannabinoid Receptor Binding Pocket with AM6538, a High-Affinity Irreversible Antagonist.

Authors:  Robert B Laprairie; Kiran Vemuri; Edward L Stahl; Anisha Korde; Jo-Hao Ho; Travis W Grim; Tian Hua; Yiran Wu; Raymond C Stevens; Zhi-Jie Liu; Alexandros Makriyannis; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2019-09-12       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.